301277.SZ深圳证券交易所 · 创业板 ChiNext
Newland Pharmaceutical 新天地
Chemical Pharmaceuticals 化学制药
¥10.24−¥0.21 · −2.01%
Open 开盘
¥10.45
High 最高
¥10.51
Low 最低
¥10.22
Prev Close 昨收
¥10.45
Volume 成交量
249.2万股
Turnover 成交额
¥2,577.3万
Mkt Cap 总市值
¥40亿
P/E 市盈率
38.6×
Recent Activity 近期动态All Filings 全部公告 →
No significant filings since 29 May 2026.
自 29 May 2026 起无重大公告。
9.0010.0011.0012.0013.00
Volume 成交量
2,426.8万
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥40亿 | ¥63亿 | 51st lowest of 158 · 158 家中第 51 低 | |
| Trailing P/E 市盈率 | 38.6x | 38.6x | 56th highest of 112 · 112 家中第 56 高 | |
| P/B 市净率 | 2.6x | 2.5x | 77th highest of 157 · 157 家中第 77 高 | |
| Revenue Growth 营收增速 | 10.6% | 1.6% | 47th highest of 156 · 156 家中第 47 高 | |
| Profit Growth 净利增速 | -22.1% | 1.9% | 52nd lowest of 158 · 158 家中第 52 低 | |
| Gross Margin 毛利率 | 30.5% | 50.2% | 39th lowest of 155 · 155 家中第 39 低 | |
| Net Margin 净利率 | 15.1% | 9.8% | 51st highest of 157 · 157 家中第 51 高 | |
| Return on Equity 净资产收益率 | 3.9% | 3.1% | 57th highest of 157 · 157 家中第 57 高 | |
| Debt to Assets 资产负债率 | 12.6% | 28.0% | 28th lowest of 158 · 158 家中第 28 低 | |
| Grade Score 评级得分 | 58 | 51 | 47th highest of 157 · 157 家中第 47 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Newland Pharmaceutical 新天地 | ¥40亿 | 38.6x | 2.6x | 10.6% | 15.1% | 3.9% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。